Finally, a study of NAFLD patients with type 2 diabetes who did not respond to incretin-based therapy showed that SGLT-2 inhibitor treatment resulted in good glycemic control, reduced body weight, normalized ALT levels, and a reduced Fibrosis-4 index (78). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.